Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bis-pyridino containing compounds for the use in the treatment of CNS pathologies

a technology of cns pathologies and bispyridino, which is applied in the direction of heterocyclic compound active ingredients, drug compositions, biocides, etc., can solve the problems that quaternary ammonium compounds cannot easily access the brain, and relatively few studies have focused on the therapeutic development of nachr antagonists, etc., to achieve the effect of inhibiting dopamine releas

Inactive Publication Date: 2005-11-24
UNIV OF KENTUCKY RES FOUND
View PDF5 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about developing compounds that can treat nicotine addiction and related conditions by blocking the action of nicotine in the brain. These compounds are made by modifying the structure of nicotine and can be applied in different ways to the patient, such as through a patch or injection. The compounds can also be used to inhibit the release of dopamine in the brain. The technical effect of this invention is the development of a new generation of compounds that can treat nicotine addiction and related conditions with greater effectiveness and selectivity.

Problems solved by technology

However, relatively few studies have focused on the therapeutic development of nAChR antagonists.
However, it is generally believed that quaternary ammonium compounds do not easily access the brain due to their charge and polarity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bis-pyridino containing compounds for the use in the treatment of CNS pathologies
  • Bis-pyridino containing compounds for the use in the treatment of CNS pathologies
  • Bis-pyridino containing compounds for the use in the treatment of CNS pathologies

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0084] N,N′-Pentane-1,5-diyl-bis-pyridinium Diiodide (bPPeI).

[0085] 1,5-Diiodopentane (mmol) was added to a solution (30 mL) of dry pyridine, and the solution heated for 24 hours at 65° C. The resulting precipitate was filtered, and the product washed five times with dry diethyl ether. The resulting yellow solid was isolated in a 90% yield. 1H NMR (300 MHz, DMSO-D6) δ 9.14 (2H, d, C2&C6-H), 8.62 (1H, t, C4-H), 8.19 (2H, t, C3&C5-H), 4.62 (2H, t, C′1-CH2), 1.92 (2H, m, C′2-CH2), 1.25 (1H, m, C′3-CH2).

example 2

[0086] N,N′-Hexane-1,6-diyl-bis-pyridinium Diiodide (bPHxI).

[0087] 1,6-Diiodohexane (mmol) was added to a solution (30 mL) of dry pyridine, and the solution heated for 24 hours at 65° C. The resulting precipitate was filtered, and the product washed five times with dry diethyl ether. The resulting yellow solid was isolated. 1H NMR (300 MHz, DMSO-D6) δ 9.11 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.18 (2H, t, C3&C5-H), 4.59 (2H, t, C′1-CH2), 1.89 (2H, m, C′2-CH2), 1.28 (2H, m, C′3-CH2).

example 3

[0088] N,N′-Octane-1,8-diyl-bis-pyridinium Diiodide (bPOI).

[0089] 1,8-Diiodooctane (mmol) was added to a solution (30 mL) of dry pyridine, and the solution heated for 24 hours at 65° C. The resulting precipitate was filtered, and the product washed five times with dry diethyl ether. The resulting yellow solid was isolated in a 93% yield. 1H NMR (300 MHz, DMSO-D6) δ 9.11 (2H, d, C2&C6-H), 8.63 (1H, t, C4-H), 8.18 (2H, t, C3&C5-H), 4.59 (2H, t, C′1-CH2), 1.89 (2H, m, C′2-CH2), 1.28 (4H, m, C′3&4-CH2); 13C NMR (75 MHz, DMSO-D6) δ 145.3, 144.5, 127.9, 60.5,30.6, 28.1, 25.2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
volumeaaaaaaaaaa
compositionaaaaaaaaaa
Login to View More

Abstract

N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for the blood-brain barrier choline transporter.

Description

RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Application Ser. No. 60 / 533,213, filed Dec. 31, 2003, which is incorporated herein in its entirety.BACKGROUND OF THE INVENTION [0002] Considerable effort has focused on the development of neuronal nicotinic receptor (nAChR) agonists as therapeutic agents. However, relatively few studies have focused on the therapeutic development of nAChR antagonists. As a result, only a few subtype-selective antagonists are currently available for use as pharmacological tools to investigate the physiological roles of specific nAChR subtypes. [0003] It has been found that nicotine stimulates all known nAChR subtypes, and that N-quaternization of nicotine converts it from an agonist into an antagonist with enhanced nAChR subtype selectivity. Several classical nAChR antagonists are bis-quaternary ammonium structures. Hexamethonium chloride and decamethonium bromide, both bis-quaternary ammonium salts, are considered simpl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/444A61K31/4709C07D213/16C07D213/22C07D215/10C07D217/10C07D401/04C07D401/14
CPCC07D213/06C07D213/22C07D401/14C07D217/10C07D215/10A61P25/00
Inventor CROOKS, PETER A.DWOSKIN, LINDA P.AYERS, JOSHUAGRINEVICH, VLADIMIRSUMITHRAN, SANGEETHA
Owner UNIV OF KENTUCKY RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com